In:
AIDS, Ovid Technologies (Wolters Kluwer Health)
Abstract:
Aim was to evaluate whether mpox vaccination with modified vaccinia Ankara-Bavarian Nordic (MVA-BN) may be associated with viral blips (VB) or confirmed virologic failures (CVF) in people with HIV (PWH) receiving antiretroviral therapy and the associated factors. Design: PWH who received MVA-BN, with HIV-RNA 〈 50copies/mL and CD4 + lymphocytes ≥200cells/μL in the 6 months prior to vaccination and ≥1 HIV-RNA determination within 3 months from vaccination. Methods: The primary outcome was occurrence of VB (1 HIV-RNA≥50 copies/mL) and CVF (1 HIV-RNA≥1000 copies/mL or ≥2 consecutive HIV-RNA≥50 copies/mL) following MVA-BN. Changes in CD4 + and CD4 + /CD8 + were secondary outcomes. Residual viremia was defined as detectable HIV-RNA 〈 50 copies/mL. PWH already vaccinated against smallpox received single-dose MVA-BN. Mann-Whitney rank-sum test or Chi-square/Fisher's test applied. Results: Overall, 187 PWH were included: 147 received two-doses of MVA-BN, 40 single-dose. Six VBs [incidence rate (IR) = 1.59/100-person months of follow-up (PMFU), 95% confidence interval (95%CI) = 0.58–3.47] and three CVFs [IR = 0.80/100-PMFU (95%CI = 0.16–2.33)] were observed. Two CVFs occurred at second dose with presence of detectable HIV-RNA following first one, with high compliance to antiretroviral therapy (ART). PWH with VBs or CVFs had, prior to first vaccination, more frequently residual viremia [77% (n = 7) versus 35% (n = 62), p = 0.01]. No differences in ART (p = 0.42) and number of MBA-BN doses (p = 0.40) was found. In two cases of CVFs ART was changed; all VBs resolved within 1 month. Conclusions: Although rare, VBs and CVFs following MVA-BN vaccination among PWH receiving ART were identified. Close monitoring of HIV-RNA during mpox vaccination should be encouraged.
Type of Medium:
Online Resource
ISSN:
0269-9370
,
1473-5571
DOI:
10.1097/QAD.0000000000003733
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2023
detail.hit.zdb_id:
2012212-3
